Skip to main content
Premium Trial:

Request an Annual Quote

NEWS BRIEF: Exelixis, Merck to Build Small-Molecule Libraries

NEW YORK, May 1 - Exelixis and pharma giant Merck will design and develop small-molecule compound libraries for high-throughput drug screening, Exelixis said today.


Both firms will own the libraries, which will be used for internal lead-discovery programs as well as in collaborative research ventures, the partners said.

Exelixis will bring to the table small molecules, analytics, informatics, and formatting.


Click here for more information.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.